01—Abstract
Summary
Summary of the 10-Q filed May 1, 2025. Cited figures are marked; the original filing is the authoritative source.
Boston Scientific Corporation reported strong financial results for the first quarter ended March 31, 2025, with net sales increasing by 20.9% year-over-year to $4.663 billiona.
This growth was driven by robust commercial execution across its business segments, notably the Electrophysiology business unit and its Farapulse™ Pulsed Field Ablation System. The company reported a net income attributable to common stockholders of $674 millionb, or $0.45 per diluted share, a significant increase from the prior year.
The company also highlighted its strategic acquisitions and upcoming integrations, including the recent completion of Cortex, Inc. and the pending acquisitions of SoniVie Ltd. and Intera Oncology, Inc. These moves underscore Boston Scientific's commitment to expanding its product portfolio and market reach, particularly in high-growth areas like cardiology and peripheral interventions. The company maintains a strong liquidity position and is in compliance with its financial covenants, demonstrating financial stability amidst ongoing global economic uncertainties.
02—Key points
Key Highlights
- Net sales surged by 20.9% to $4.663 billion for the first quarter of 2025, driven by strong global commercial execution.
- Net income attributable to common stockholders was $674 million, or $0.45 per diluted share, up from $495 million, or $0.33 per diluted share, in the prior year.
- The Electrophysiology business unit, particularly the Farapulse™ Pulsed Field Ablation System, was a key growth driver.
- Acquisition activity remains robust with the completion of Cortex, Inc. and pending acquisitions of SoniVie Ltd. and Intera Oncology, Inc.
- Gross profit margin improved slightly to 68.8% due to higher-margin product sales.
- SG&A expenses increased but decreased as a percentage of net sales, reflecting improved operational leverage.
- The company reported a strong liquidity position with $725 million in unrestricted cash and cash equivalents and no outstanding amounts under its revolving credit facility.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2025, Boston Scientific Corp kept $0.14.
- Revenue$4.66B100.0%
- Cost of revenue−$1.45B31.2%
- Gross profit$3.21B68.8%
- Operating costs−$2.29B49.1%
- Operating income$921.0M19.8%
- Interest, other & tax−$247.0M5.3%
- Net income$674.0M14.5%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed May 1, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $4.66B$3.86B | +20.9% |
| Cost of Revenue | $1.45B$1.21B | +20.2% |
| Gross Profit | $3.21B$2.65B | +21.2% |
| SG&A Expenses | $1.60B$1.36B | +17.1% |
| Operating Expenses | $2.29B$1.97B | +16.0% |
| Operating Income | $921.00M$675.00M | +36.4% |
| Interest Expense | $82.00M$69.00M | +18.8% |
| Net Income | $674.00M$495.00M | +36.2% |
| EPS (Basic) | $0.46$0.34 | +35.3% |
| EPS (Diluted) | $0.45$0.33 | +36.4% |
| Shares Outstanding (Basic) | 1.48B1.47B | +0.6% |
| Shares Outstanding (Diluted) | 1.49B1.48B | +0.8% |
05—Questions
Frequently Asked Questions
What drove the significant increase in net sales for Boston Scientific in the first quarter of 2025?
The significant increase in net sales was primarily driven by strong commercial execution across all business segments, with notable growth in the Electrophysiology business unit, largely attributed to the successful adoption of the Farapulse™ Pulsed Field Ablation System. Overall operational net sales growth was 22.2%, reflecting strong organic growth and contributions from recent acquisitions.
How is Boston Scientific managing its acquisition strategy, and what are the key recent/pending deals?
Boston Scientific continues to pursue a robust acquisition strategy to expand its product portfolio. In the first quarter of 2025, they completed the acquisition of Cortex, Inc. They also announced definitive agreements to acquire SoniVie Ltd. and Intera Oncology, Inc., expected to close in the second quarter of 2025. These acquisitions are strategically focused on bolstering their cardiology and peripheral intervention offerings.
What is the company's financial health and liquidity position based on this report?
Boston Scientific demonstrates a strong financial position. They reported $725 million in unrestricted cash and cash equivalents as of March 31, 2025. Furthermore, they had no amounts outstanding under their $2.750 billion revolving credit facility, indicating ample liquidity. The company is also in compliance with its financial covenants, with a leverage ratio of 2.21 times compared to a maximum permitted of 4.75 times.
Are there any significant legal or regulatory matters that investors should be aware of?
The company is involved in various ongoing legal proceedings, including patent litigation related to its Synergy™ Stent System, product liability litigation concerning transvaginal surgical mesh, and governmental investigations into its operations, particularly concerning alleged Foreign Corrupt Practices Act (FCPA) violations in Vietnam. While the company accrues for probable and estimable losses, the outcomes of these matters remain uncertain and could materially impact financial results.
06—Continue